- Kempf, Dale J.; Norbeck, Daniel W.; Sham, Hing Leung; Zhao, Chen; Sowin, Thomas J.; Reno, Daniel S.; Haight, Anthony R.; Cooper, Arthur J., Retroviral Protease Inhibiting Compounds, Abbott Laboratories, United States, EP674513B1, September 25, 1996
- Marsh, Kennan C.; Eiden, Erin; McDonald, Edith, Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography, Journal of Chromatography B: Biomedical Sciences and Applications, Volume: 704, Issue: 1 + 2, Pages: 307-313, 1997
Frequently Asked Questions
Ritonavir impurities are evaluated throughout its shelf life to ensure the medicine maintains quality and meets permissible impurity levels.
Ritonavir impurities form during the synthetic process from starting materials or as degradation products due to various factors such as reaction conditions, impurities in raw materials, or storage conditions.
Specific acceptance criteria are established for Ritonavir impurities to ensure their levels remain within defined limits and according to regulatory guidelines.
Ritonavir impurities can be related to the quality and efficiency of the drug.
Ritonavir impurities should be stored at a controlled room temperature between 2-8°C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.